India Globalization Capital, Inc. (NYSE: IGC) Preparing to Bring Cannabis Combo Therapy for Alzheimer’s Disease to Trials
Four drug candidates in the pipeline Potential sales of Alzheimer’s drugs run to billions Hyalolex heading for clinical trials India Globalization Capital, Inc. (NYSE MKT: IGC) is racing ahead with its preparation of medical trials for four drug candidates that treat a variety of debilitating conditions. At the head of the line is Hyalolex, aimed at reducing the buildup of amyloid β-peptide (Aβ) plaques on neurons in the brain, a process that causes the crippling cognitive complaint known as Alzheimer’s disease. Alzheimer’s afflicts more than five million Americans, and, so far, no effective cure for this form of dementia has…